Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir
MarketBeat ·